The use of slow-release drugs in stents (drug-eluting stents) has dramatically reduced restenosis rates after percutaneous coronary intervention. However, these permanent metal devices may impair ...

There is no doubt that permanent metallic stents have well-known limitations. First, their use requires prolonged antiplatelet therapy and is associated with various rates of thrombosis. In addition, ...

CHICAGO--When pioneering interventional cardiologists introduced angioplasty and stenting more than 20 years ago, few could have imagined that, one day, severely diseased coronary arteries would be ...

A study published today online in The Lancet (March 13, 2009) presented two year data for the bioabsorbable everolimus coronary stent. Commenting on the results, interventional cardiology specialist, ...

Barcelona, Spain and London, UK - Updates from bioabsorbable-stent trials suggest that investigators are making incremental improvements to devices that might one day be used for coronary ...

Abbott said it will monitor bioabsorbable stent implantations in Europe, following a high rate of heart attacks in European Absorb GT1 patients, plus a separate FDA safety alert regarding adverse ...

Being the first to get the FDA approval for a bioabsorbable polymer drug-eluting stent (BP-DES), Boston Scientific has a huge opportunity to gain share in the interventional cardiology market in the ...

The use of slow-release drugs in stents (drug-eluting stents, or DES) has dramatically reduced restenosis rates after percutaneous coronary intervention (PCI) compared to early bare-metal stent ...

A new study presented two-year data for the bioabsorbable everolimus coronary stent. An interventional cardiology specialist and official spokesperson for the European Society of Cardiology has ...